

## OBJECTIVES:

1. Learn about the effectiveness of nirsevimab prophylaxis in Quebec.
2. Recognize the burden of RSV disease among Indigenous children and the effectiveness of nirsevimab.
3. Appreciate risk factors associated with severe clinical outcomes among children hospitalized with RSV.
4. Appreciate the effectiveness of nirsevimab and the RSVpreF vaccine against medically attended RSV infection and hospitalization in the USA.
5. Recognize that nirsevimab may be more effective than RSVpreF to reduce the risk and severity of hospitalization.
6. Recognize the impact of a combined RSVpreF vaccine and nirsevimab strategy on RSV hospitalization in Luxembourg.
7. Learn about inequalities in access to RSV prophylaxis products in the UK and globally.
8. Appreciate the global impact of breastfeeding on the incidence and severity of acute RSV infection.
9. Appreciate the efficacy of clesrovimab against RSV infection in preterm and term infants.
10. Learn about new interventions on the horizon for the treatment of RSV.
11. Appreciate factors governing the choice of RSV prophylaxis products for disease prevention.
12. Appreciate the changes for the 2026-2027 RSV season as dictated by the Ontario Ministry of Health and the Medical Officer of Health.

This event has been approved by the Canadian Paediatric Society for a maximum of 6 credit hours as an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada.

The specific opinions and content of this event are not necessarily those of the CPS and are the responsibility of the organizer(s) alone.

## FURTHER INFORMATION

Please Contact

Dr. Bosco Paes  
[paes@mcmaster.ca](mailto:paes@mcmaster.ca)

Louise Bruns  
Program Coordinator  
[louise@brunsconsulting.ca](mailto:louise@brunsconsulting.ca)



McMaster Children's Hospital  
Presents

## RSV CONFERENCE

INTERACTIVE LIVE  
VIRTUAL CONFERENCE

Bridging research evidence  
into clinical practice

Wednesday  
September 23,  
2026

## PROGRAMME COMMITTEE

**Dr. Bosco Paes**  
**Dr. Jeffrey Pernica**  
**Dr. Sandra Seigel**

## SPEAKERS

Jesse Papenburg, MD, MSc, FRCPC  
Division of Pediatric Infectious Diseases  
McGill University

David Goldfarb, MD, FRCPC  
Pathology/Laboratory Medicine  
University of British Columbia

Peter Gill, MD, DPhil, MSc  
Scientist SickKids Research Institute  
Pediatrics, University of Toronto

Heidi Moline, MD, MPH,  
Epidemiologist New Vaccine Surveillance  
Network, CDC; Pediatrics,  
University of Minnesota

Marie-Joelle Jabagi, PharmD, PhD, MPH  
French National Agency for Medicines and  
Health Products Safety; Université Paris-Saclay

Corinna Ernst, MSc, PhD  
Public Health and EPIET Fellow  
Health Directorate Luxembourg  
University of Cologne

James Charlesworth, PhD, MRCPCH  
Department of Paediatrics, University of Oxford  
United Kingdom

Roy Philip, MD, FRCPI, FRCPC  
Division of Neonatology  
University of Limerick, Ireland

Helen Chu, MD, MPH  
Allergy & Infectious Diseases; Associate Dean for  
Research, University of Washington

John DeVincenzo, MD  
Vice President of Translational Virology  
ENANTA Pharmaceuticals, USA

Janet Englund, MD  
Division of Pediatric Infectious Diseases  
Seattle Children's Hospital; University of Washington

Daniel Warshafsky, MD, MPH, FRCPC  
Associate Chief Medical Officer of Health  
Office of the Chief Medical Officer of Health  
Public Health

- 7:30-8:00 **REGISTRATION**
- 8:00-8:15 **INTRODUCTION** – Dr. B. Paes
- 8:15-8:45 Nirsevimab effectiveness on severe RSV outcomes in Quebec. Dr. J. Papenburg
- 8:45-9:15 Nirsevimab outcomes in Indigenous populations. Dr. D. Goldfarb
- 9:15-9:45 Risk factors for severe RSV disease among hospitalized children. Dr. P. Gill
- 9:45-10:00 **BREAK**
- 10:00-10:30 Effectiveness of maternal vaccine and nirsevimab on medically attended RSV infection and hospitalization. Dr. H. Moline
- 10:30-11:00 Nirsevimab vs. RSVpreF vaccine to reduce the risk and severity of hospitalization. Dr. M-J Jabagi
- 11:00-11:30 Maximizing RSV prevention with combined RSVpreF vaccine and nirsevimab. Dr. C. Ernst
- 11:30-12:00 Aborting inequality in the current UK and global RSV immunization approach. Dr. J. Charlesworth
- 12:00-12:30 **LUNCH**
- 12:30-13:00 Global impact of breastfeeding on the incidence and severity of acute RSV infection. Dr. R. Philip
- 13:00-13:30 Clesrovimab - the new kid on the block for RSV prevention in healthy and preterm infants. Dr. H. Chu
- 13:30-14:00 Emerging treatment strategies for young children with active RSV infections. Dr. J. DeVincenzo
- 14:00-14:15 **BREAK**
- 14:15-14:45 Factors influencing the choice of RSV immunization strategies for children. Dr. J. Englund
- 14:45-15:15 The Provincial MOH for Infant RSV Program (2026-2027) season: logistics for the application, receipt and distribution of prophylaxis. Dr. D. Warshafsky
- 15:15-15:30 **EVALUATIONS AND CONCLUSION**

# RSV CONFERENCE

**Bridging research evidence  
into clinical practice**

**Wednesday,  
September 23,  
2026**

**NO REGISTRATION FEES!**  
Join us for the interactive live  
virtual conference!

Only preregistered attendees will be  
admitted.

Register online at:  
[www.mcmaster-pediatrics.ca](http://www.mcmaster-pediatrics.ca)